![ELOCTATE® (Antihemophilic Factor Recombinant), Fc Fusion Protein]](/Content/images/eloctate-logo.svg){kind=logo}
JONATHAN EMBODIES DRIVE AND AMBITION
Jonathan is widely known as “the car guy,” and rightly so. But when he's not detailing a hot rod, he's studying the details of his Hemophilia A treatment. That's why he worked with his doctor, and made the switch from ADVATE® to ELOCTATE.
*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.
ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a Takeda company.
Q&A
How long have you been working on cars?
When I was a kid, my grandfather had a mechanic shop. I fell in love, and the rest is history.
What about ELOCTATE led you to switch from ADVATE®?
What intrigued me was the extended half-life and the possibility of an infusion schedule up to five days. I mean, everybody is different, but once I worked with my doctor I realized this was the best choice for me.
How's it working out for you, so far?
It's great. I went from infusing every other day on my previous standard half life factor to infusing every 4 days on ELOCTATE. But kinda like cars, each one of us is a different make, a different model, and requires different, specialized care.
So, what's next for “the car guy”?
I once built a car from scratch. It might be time for a new one.
Note: Patient stories reflect the real-life experiences of persons diagnosed with hemophilia A who have been prescribed ELOCTATE. However, individual experiences may vary. Patient stories are not necessarily representative of what another person using ELOCTATE may experience. Talk to your healthcare provider about what's right for you. ELOCTATE Peers™ have been compensated for sharing their stories.
The recommended starting regimen is 50 IU/kg every 4 days as directed by your doctor. In children under 6 years of age, the recommended starting regimen is 50 IU/kg administered twice weekly. The regimen can be adjusted based on your body's individual response.
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
IMPORTANT SAFETY INFORMATION AND INDICATION
+
IMPORTANT SAFETY INFORMATION
Do not use ELOCTATE if you have had an allergic reaction to it in the past.
Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.
Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.
Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.
If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.
These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.
INDICATION
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
PLEASE SEE FULL PRESCRIBING INFORMATIONMANUFACTURED BY
Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078
CLICK HERE TO LEARN MORE ABOUT SANOFI'S COMMITMENT TO FIGHTING COUNTERFEIT DRUGS.
INDICATION
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
MAT-US-2021672-V7.0-05/2023 LAST UPDATED: MAY 2023